Very interesting developments though I view this is nothing more than speculation by people on various Yahoo message boards until I see further success on FDA trials. Perhaps stock didn’t deserve to be at 0.25-0.30 in the first place and this better reflects company risk-adjusted potential (which is far from a sure thing). I’m holding my shares for now as any positive developments could push this soaring into the couple dollar range. I also wish the stock had better liquidity but people should understand market orders aren’t a good idea with VODG.
Market Data 
Markets 
AI
